Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

Broadens Lilly's immunology pipeline with Morphic's oral integrin therapies, including MORF-057

Reinforces the company's strategy of delivering potential first or best-in-class therapies in the field of gastroenterology

Read more at prnewswire.com